Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that management will host a conference call on Monday, November 26th , 2018, at 8:30 a.m. ET to reveal their first adeno-associated viral vector (AAV) gene therapy program.
November 25, 2018
· 1 min read